Eli Lilly's Dominance in the GLP-1 Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Source: Fool
- Market Leadership: Eli Lilly commands over 60% of the GLP-1 drug market, with Mounjaro and Zepbound driving consistent revenue growth, as evidenced by over $11 billion in combined revenue last quarter, showcasing its competitive edge in the rapidly expanding obesity drug sector.
- Revenue Growth Potential: Analysts project the obesity drug market to approach $100 billion by the end of the decade, and with Lilly's robust position and product pipeline, the company is well-positioned for sustained revenue growth over the coming decades, potentially delivering substantial returns for shareholders.
- Product Efficacy Advantage: Zepbound's superior performance in head-to-head trials against Wegovy further solidifies Lilly's market leadership, while the anticipated approval of orforglipron, which offers easier administration, is expected to generate additional growth and enhance the company's competitive stance.
- Diversified Investment Opportunity: While Eli Lilly alone may not make investors millionaires, its stock remains a valuable component of a diversified portfolio, particularly as the obesity drug market continues to expand, providing potential for significant wealth accumulation for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1041.650
Low
950.00
Averages
1192
High
1500
Current: 1041.650
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Positive Phase 1b Results for VERVE-102 in Cardiovascular Treatment
- Clinical Trial Results: In the Phase 1b Heart-2 trial, VERVE-102 demonstrated dose-dependent reductions in PCSK9 and LDL-C, with PCSK9 decreasing by 51% to 88% and LDL-C by 9% to 62%, indicating its potential efficacy in high-risk cardiovascular patients.
- Long-term Effectiveness: Among 35 participants, the LDL-C reduction from VERVE-102 was sustained for up to 18 months post-treatment, suggesting that the drug may offer durable cardiovascular protection, addressing the urgent need for new therapies.
- FDA Fast Track Designation: VERVE-102 has received Fast Track designation from the FDA, aimed at providing new treatment options for patients with hyperlipidemia and high cardiovascular risk, highlighting its potential market value and significance.
- Future Research Plans: Lilly plans to initiate the Phase 2 clinical study by the end of this year to further validate the safety and efficacy of VERVE-102, potentially transforming cardiovascular care from chronic management to a one-time treatment.
See More
Wall Street Trading Week Outlook and Focus
- Salesforce Earnings Outlook: Salesforce is set to report earnings on Wednesday, with market concerns about its AI business still prevalent; analysts expect revenue of $11.05 billion and EPS of $3.12, and strong revenue growth could alleviate worries about slowing growth in its legacy business.
- Costco Membership Renewal Challenges: Costco will report earnings on Thursday, with expected revenue of $69.73 billion and EPS of $4.93; while high oil prices may pressure profit margins, its membership model and bulk selling strategy are likely to attract consumers, especially during periods of rising gas prices.
- Economic Data Focus: The personal consumption expenditures (PCE) price index will be released on Thursday, with a year-over-year increase expected at 3.8% and a core increase of 3.3%, which will influence the Federal Reserve's rate hike decisions, leaving the market uncertain about future rate changes.
- Investor Conference Season: This week marks the start of investor conference season, with Boeing, Johnson & Johnson, and others attending the Bernstein Strategic Decisions Conference, where analyst questions may reveal insights into market perceptions of company futures, making it a key event to watch.
See More
Positive Phase 1b Results for VERVE-102 in Lowering LDL-C
- Clinical Trial Results: In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 achieved dose-dependent reductions in PCSK9 and LDL-C, with PCSK9 reductions ranging from 51% to 88% and LDL-C reductions from 9% to 62%, indicating its potential efficacy in high-risk cardiovascular patients.
- Long-Term Effects: These reductions were sustained for up to 18 months post-treatment, suggesting that VERVE-102 may offer a durable treatment option for patients struggling with existing therapies, thereby addressing a significant unmet medical need.
- FDA Fast Track Designation: VERVE-102 has received Fast Track designation from the FDA, aimed at providing a new treatment avenue for patients with hyperlipidemia and high cardiovascular risk, highlighting its potential market significance and demand.
- Future Research Plans: Lilly plans to initiate the Phase 2 clinical study by the end of this year to further validate the safety and efficacy of VERVE-102, which is expected to revolutionize the treatment landscape for cardiovascular diseases.
See More
Goldman Sachs Recommends Non-AI Stock Investments
- Market Trend Analysis: Goldman Sachs highlights that despite the dominance of AI trades pushing the S&P 500 and Nasdaq to multiple record highs this year, there are still noteworthy non-AI companies to invest in, indicating market diversity and potential opportunities.
- Portfolio Recommendations: Goldman analysts suggest a portfolio of Russell 1000 stocks with low sensitivity to both AI trades and economic growth pricing, which have recently seen positive earnings revisions by analysts, indicating fundamental support for these investments.
- Eli Lilly Outlook: Although Eli Lilly's stock has slipped about 1% this year, Goldman believes only 9% of its recent returns are driven by the U.S. economic outlook and AI, while Morgan Stanley's analyst sets a $1,344 price target, implying a 26.2% upside potential.
- Fortinet Strong Performance: Fortinet has surged 68.7% this year, with Goldman attributing 19% of its returns to the U.S. economic outlook and AI; BTIG upgraded its rating to buy with a $125 price target, reflecting confidence in its mid-term revenue growth prospects.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
Positive Phase 1b Results for VERVE-102 in Cardiovascular Treatment
- Clinical Trial Results: In the Phase 1b Heart-2 trial, VERVE-102 demonstrated dose-dependent reductions in PCSK9 and LDL-C, with PCSK9 decreasing by 51% to 88% and LDL-C by 9% to 62%, indicating its potential efficacy in high-risk cardiovascular patients.
- Long-term Effectiveness: Among 35 participants, the LDL-C reduction from VERVE-102 was sustained for up to 18 months post-treatment, suggesting that the drug may offer durable cardiovascular protection, addressing the urgent need for new therapies.
- FDA Fast Track Designation: VERVE-102 has received Fast Track designation from the FDA, aimed at providing new treatment options for patients with hyperlipidemia and high cardiovascular risk, highlighting its potential market value and significance.
- Future Research Plans: Lilly plans to initiate the Phase 2 clinical study by the end of this year to further validate the safety and efficacy of VERVE-102, potentially transforming cardiovascular care from chronic management to a one-time treatment.
See More
Wall Street Trading Week Outlook and Focus
- Salesforce Earnings Outlook: Salesforce is set to report earnings on Wednesday, with market concerns about its AI business still prevalent; analysts expect revenue of $11.05 billion and EPS of $3.12, and strong revenue growth could alleviate worries about slowing growth in its legacy business.
- Costco Membership Renewal Challenges: Costco will report earnings on Thursday, with expected revenue of $69.73 billion and EPS of $4.93; while high oil prices may pressure profit margins, its membership model and bulk selling strategy are likely to attract consumers, especially during periods of rising gas prices.
- Economic Data Focus: The personal consumption expenditures (PCE) price index will be released on Thursday, with a year-over-year increase expected at 3.8% and a core increase of 3.3%, which will influence the Federal Reserve's rate hike decisions, leaving the market uncertain about future rate changes.
- Investor Conference Season: This week marks the start of investor conference season, with Boeing, Johnson & Johnson, and others attending the Bernstein Strategic Decisions Conference, where analyst questions may reveal insights into market perceptions of company futures, making it a key event to watch.
See More
Positive Phase 1b Results for VERVE-102 in Lowering LDL-C
- Clinical Trial Results: In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 achieved dose-dependent reductions in PCSK9 and LDL-C, with PCSK9 reductions ranging from 51% to 88% and LDL-C reductions from 9% to 62%, indicating its potential efficacy in high-risk cardiovascular patients.
- Long-Term Effects: These reductions were sustained for up to 18 months post-treatment, suggesting that VERVE-102 may offer a durable treatment option for patients struggling with existing therapies, thereby addressing a significant unmet medical need.
- FDA Fast Track Designation: VERVE-102 has received Fast Track designation from the FDA, aimed at providing a new treatment avenue for patients with hyperlipidemia and high cardiovascular risk, highlighting its potential market significance and demand.
- Future Research Plans: Lilly plans to initiate the Phase 2 clinical study by the end of this year to further validate the safety and efficacy of VERVE-102, which is expected to revolutionize the treatment landscape for cardiovascular diseases.
See More
Goldman Sachs Recommends Non-AI Stock Investments
- Market Trend Analysis: Goldman Sachs highlights that despite the dominance of AI trades pushing the S&P 500 and Nasdaq to multiple record highs this year, there are still noteworthy non-AI companies to invest in, indicating market diversity and potential opportunities.
- Portfolio Recommendations: Goldman analysts suggest a portfolio of Russell 1000 stocks with low sensitivity to both AI trades and economic growth pricing, which have recently seen positive earnings revisions by analysts, indicating fundamental support for these investments.
- Eli Lilly Outlook: Although Eli Lilly's stock has slipped about 1% this year, Goldman believes only 9% of its recent returns are driven by the U.S. economic outlook and AI, while Morgan Stanley's analyst sets a $1,344 price target, implying a 26.2% upside potential.
- Fortinet Strong Performance: Fortinet has surged 68.7% this year, with Goldman attributing 19% of its returns to the U.S. economic outlook and AI; BTIG upgraded its rating to buy with a $125 price target, reflecting confidence in its mid-term revenue growth prospects.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
